Skip to content

Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA)

Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA) - Diagnostic Performance of PSMA-PET

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000037697
Enrollment
250
Registered
2019-09-01
Start date
2019-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Sponsors

Osaka University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Adult men who meet any one of the following criteria: (1) Patient who is diagnosed as prostate cancer, and undergo CT and/or bone scintigraphy or will undergo. (2) Patient who represent PSA elevation after local treatment (surgery or radiotherapy) for prostate cancer, and undergo CT and/or bone scintigraphy or will undergo (so-called PSA failure) (3) Patient with castration-resistant prostate cancer without metastasis on CT or bone scintigraphy who will undergo treatment using oral androgen receptor signaling inhibitors (4) Patient with castration-resistant prostate cancer who is confirmed metastasis by CT and/or bone scintigraphy

Exclusion criteria

Exclusion criteria: (1) Patient who cannot keep the body position for 30 minutes. (2) Others who are regarded as unsuitable for enrollment in the opinion of research staff.

Design outcomes

Primary

MeasureTime frame
1) PSMA-PET findings compared with conventional imaging findings of CT / bone scintigraphy etc. before treatment

Secondary

MeasureTime frame
2) Comparison of pathological findings after surgery or biopsy and PSMA-PET-positive lesions 3) Follow-up of PSMA-PET compared to conventional imaging findings of CT / bone scintigraphy etc. after treatment

Countries

Japan

Contacts

Public ContactTasashi Watabe

Osaka University Graduate School of Medicine Nuclear Medicine and Tracer Kinetics

watabe@tracer.med.osaka-u.ac.jp06-6879-3461

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026